These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 22532795)

  • 1. Computational design of a PDZ domain peptide inhibitor that rescues CFTR activity.
    Roberts KE; Cushing PR; Boisguerin P; Madden DR; Donald BR
    PLoS Comput Biol; 2012; 8(4):e1002477. PubMed ID: 22532795
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The relative binding affinities of PDZ partners for CFTR: a biochemical basis for efficient endocytic recycling.
    Cushing PR; Fellows A; Villone D; Boisguérin P; Madden DR
    Biochemistry; 2008 Sep; 47(38):10084-98. PubMed ID: 18754678
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Golgi-associated PDZ domain protein modulates cystic fibrosis transmembrane regulator plasma membrane expression.
    Cheng J; Moyer BD; Milewski M; Loffing J; Ikeda M; Mickle JE; Cutting GR; Li M; Stanton BA; Guggino WB
    J Biol Chem; 2002 Feb; 277(5):3520-9. PubMed ID: 11707463
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting CAL as a negative regulator of DeltaF508-CFTR cell-surface expression: an RNA interference and structure-based mutagenetic approach.
    Wolde M; Fellows A; Cheng J; Kivenson A; Coutermarsh B; Talebian L; Karlson K; Piserchio A; Mierke DF; Stanton BA; Guggino WB; Madden DR
    J Biol Chem; 2007 Mar; 282(11):8099-109. PubMed ID: 17158866
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stereochemical preferences modulate affinity and selectivity among five PDZ domains that bind CFTR: comparative structural and sequence analyses.
    Amacher JF; Cushing PR; Brooks L; Boisguerin P; Madden DR
    Structure; 2014 Jan; 22(1):82-93. PubMed ID: 24210758
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Crystallization and preliminary diffraction analysis of the CAL PDZ domain in complex with a selective peptide inhibitor.
    Amacher JF; Cushing PR; Weiner JA; Madden DR
    Acta Crystallogr Sect F Struct Biol Cryst Commun; 2011 May; 67(Pt 5):600-3. PubMed ID: 21543871
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The CFTR trafficking mutation F508del inhibits the constitutive activity of SLC26A9.
    Bertrand CA; Mitra S; Mishra SK; Wang X; Zhao Y; Pilewski JM; Madden DR; Frizzell RA
    Am J Physiol Lung Cell Mol Physiol; 2017 Jun; 312(6):L912-L925. PubMed ID: 28360110
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The CFTR-Associated Ligand Arrests the Trafficking of the Mutant ΔF508 CFTR Channel in the ER Contributing to Cystic Fibrosis.
    Bergbower E; Boinot C; Sabirzhanova I; Guggino W; Cebotaru L
    Cell Physiol Biochem; 2018; 45(2):639-655. PubMed ID: 29402832
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A stabilizing influence: CAL PDZ inhibition extends the half-life of ΔF508-CFTR.
    Cushing PR; Vouilleme L; Pellegrini M; Boisguerin P; Madden DR
    Angew Chem Int Ed Engl; 2010 Dec; 49(51):9907-11. PubMed ID: 21105033
    [No Abstract]   [Full Text] [Related]  

  • 10. Ubiquitination and degradation of CFTR by the E3 ubiquitin ligase MARCH2 through its association with adaptor proteins CAL and STX6.
    Cheng J; Guggino W
    PLoS One; 2013; 8(6):e68001. PubMed ID: 23818989
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Syntaxin 6 and CAL mediate the degradation of the cystic fibrosis transmembrane conductance regulator.
    Cheng J; Cebotaru V; Cebotaru L; Guggino WB
    Mol Biol Cell; 2010 Apr; 21(7):1178-87. PubMed ID: 20130090
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting autophagy as a novel strategy for facilitating the therapeutic action of potentiators on ΔF508 cystic fibrosis transmembrane conductance regulator.
    Luciani A; Villella VR; Esposito S; Gavina M; Russo I; Silano M; Guido S; Pettoello-Mantovani M; Carnuccio R; Scholte B; De Matteis A; Maiuri MC; Raia V; Luini A; Kroemer G; Maiuri L
    Autophagy; 2012 Nov; 8(11):1657-72. PubMed ID: 22874563
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cyclic Peptidyl Inhibitors against CAL/CFTR Interaction for Treatment of Cystic Fibrosis.
    Dougherty PG; Wellmerling JH; Koley A; Lukowski JK; Hummon AB; Cormet-Boyaka E; Pei D
    J Med Chem; 2020 Dec; 63(24):15773-15784. PubMed ID: 33314931
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hybrid organic-inorganic inhibitors of a PDZ interaction that regulates the endocytic fate of CFTR.
    Kundu R; Cushing PR; Popp BV; Zhao Y; Madden DR; Ball ZT
    Angew Chem Int Ed Engl; 2012 Jul; 51(29):7217-20. PubMed ID: 22700245
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cysteine modifiers suggest an allosteric inhibitory site on the CAL PDZ domain.
    Zhao Y; Cushing PR; Smithson DC; Pellegrini M; Pletnev AA; Al-Ayyoubi S; Grassetti AV; Gerber SA; Guy RK; Madden DR
    Biosci Rep; 2018 Aug; 38(4):. PubMed ID: 29472314
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemically modified peptide scaffolds target the CFTR-associated ligand PDZ domain.
    Amacher JF; Zhao R; Spaller MR; Madden DR
    PLoS One; 2014; 9(8):e103650. PubMed ID: 25136860
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of the cystic fibrosis transmembrane regulator with CAL: structural features and molecular dynamics.
    Piserchio A; Fellows A; Madden DR; Mierke DF
    Biochemistry; 2005 Dec; 44(49):16158-66. PubMed ID: 16331976
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Computational Analysis of Energy Landscapes Reveals Dynamic Features That Contribute to Binding of Inhibitors to CFTR-Associated Ligand.
    Holt GT; Jou JD; Gill NP; Lowegard AU; Martin JW; Madden DR; Donald BR
    J Phys Chem B; 2019 Dec; 123(49):10441-10455. PubMed ID: 31697075
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modulation of mature cystic fibrosis transmembrane regulator protein by the PDZ domain protein CAL.
    Cheng J; Wang H; Guggino WB
    J Biol Chem; 2004 Jan; 279(3):1892-8. PubMed ID: 14570915
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interaction with cystic fibrosis transmembrane conductance regulator-associated ligand (CAL) inhibits beta1-adrenergic receptor surface expression.
    He J; Bellini M; Xu J; Castleberry AM; Hall RA
    J Biol Chem; 2004 Nov; 279(48):50190-6. PubMed ID: 15358775
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.